The proportion of resources involved in pharmaceutical product development has shifted from drug and biotechnology companies to contract Clinical Research Organizations (CROs) over the last five years, according to a survey by the Tufts Center for the Study of Drug Development. The realignment has increased the speed and efficiency of the industry's product-development pipeline while maintaining clinical-trial data quality and high levels of regulatory compliance, the study found.

Yahoo News (http://biz.yahoo.com/prnews/060123/dcm014.html?.v=33)